Aurobindo Pharma will be reporting its June-quarter earnings on Wednesday and analysts expect the company to report a double-digit profit growth this time. \tRevenue growth is seen around 22 percent, EBITDA at around 33 percent, margins 20 percent and profit growth of 32 percent. \tExpect the US business to again come off marginally on a quarter-on-quarter basis, but the US business is expected to reflect steady sales of a drug Ertapenem. \tThe rest of the world business, it is expected to grow around 20-25 percent. Aurobindo Pharma doesn't have any presence in India or minimal presence in India and the commentary from the management will be important considering the kind of regulatory issues that they have faced as well as the Sandoz acquisition, net debt all of those issues would be watched out for.